Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.
about
Protecting children from environmental toxinsWhat is the functional role of the thalidomide binding protein cereblon?Thalidomide-induced teratogenesis: history and mechanismsHuman Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data GenerationStemina biomarker discovery.Identifying critical windows of exposure for children's health.Thalidomide: the tragedy of birth defects and the effective treatment of disease.Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells.Teratogenic effects of thalidomide: molecular mechanisms.Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Long-term follow-up of thalidomide embryopathy: malformations and development of osteoarthritis in the lower extremities and evaluation of upper extremity function.Ocular coloboma: a reassessment in the age of molecular neuroscience.State of knowledge of Cameroonian drug prescribers on pharmacovigilance.Evaluating chemical and other agent exposures for reproductive and developmental toxicity.In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems.Review of animal models for autism: implication of thyroid hormone.Thalidomide-induced limb abnormalities in a humanized CYP3A mouse modelWhat can we learn from the thalidomide experience: an ophthalmologic perspective.Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age.A safety assessment of tumor necrosis factor antagonists during pregnancy.Deciphering the mystery of thalidomide teratogenicity.Fetal outcome after prenatal exposure to chemotherapy and mechanisms of teratogenicity compared to alcohol and smoking.Versican is a potential therapeutic target in docetaxel-resistant prostate cancerMedical uses of marijuana (Cannabis sativa): fact or fallacy?Thalidomide induces apoptosis in undifferentiated human induced pluripotent stem cells.Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6.Exposure-disease continuum for 2-chloro-2'-deoxyadenosine, a prototype ocular teratogen. 1. Dose-response analysis.Offspring of male and female parents with thalidomide embryopathy: birth defects and functional anomalies.Placental Drug Transport-on-a-Chip: A Microengineered In Vitro Model of Transporter-Mediated Drug Efflux in the Human Placental Barrier.Behavioral characterization of cereblon forebrain-specific conditional null mice: a model for human non-syndromic intellectual disability.Structural basis of thalidomide enantiomer binding to cereblon.Thalidomide embryopathy: Follow-up of cases born between 1959 and 2010.Studying significance of apoptosis in mediating tolbutamide-induced teratogenesis in vitro.Thalidomide Embryopathy: An Enigmatic ChallengeBig risks in small groups: The difference between epidemiology and counselling
P2860
Q21144739-5304F5D4-D975-420B-B6F7-76A9A5ABB62DQ24635072-E8516515-04B1-46F9-848B-F32A850DF9B3Q28085087-211EAACC-B8C1-4B3B-989A-0C7BBB8D0D6DQ30978080-3B8B0B96-6405-467F-BCF8-A37A2CD96CD0Q33363682-DEC5CE7F-6CE2-450B-9CCF-C9BD6DD4FC19Q33942464-5AA62D10-CDC4-4CB4-AE17-1A30CD0B3A31Q34179690-A6B5B990-4EB9-4F4F-BDFD-AFDEA8ACF4B5Q34406463-9A3C1C05-153E-4AA0-BFA5-1DE69795EB82Q34660391-CFAD068D-EC00-48C8-A868-97940FE180B3Q34999895-E24C9592-84BE-4C8E-BB05-DEF8AF070A22Q35171777-D3FFBAE4-789C-4FA0-BBE0-04B8026520B8Q35336255-BCCEFC58-3579-4F60-A66B-86C3E6069C54Q35444452-E9A94AFB-4B9C-4E6E-8C19-6F3C32DA10A2Q35668333-E399E284-F69B-4FA3-94D3-41A55DAB96A9Q35809807-0DE63705-0397-4031-8F7C-61B1784A7506Q36001001-3A002745-C66A-4B6F-932B-0329A7E90DE7Q36462150-6AF2907D-9D30-4FBC-B51E-A43FAE4CB265Q36606177-A6C4C625-0CB6-4C46-A653-FAC7E1B239B7Q37019889-767373ED-5D1A-4F72-96EA-34CF11F6DD17Q37505457-2AB5E13C-B919-4A9B-9F7D-8FC49B2B62CEQ37724349-7AE5C2AD-EA5C-4302-B25D-B5BB2FD98514Q37986238-727C048B-4D56-4325-B09B-90E749FFAE16Q38266407-64F035E9-7A6D-4C25-A69A-A4C913B517F8Q38464804-E96E33F4-05F0-4786-994E-C9913834105DQ38540829-3B081D63-E5EB-48B1-A01F-E1B12160E010Q38636369-5827F65D-20E9-4B0B-8F9C-6A2B8F3BEF4FQ39549782-46AA0FA3-B7F4-4408-92D5-E0F2B82A8E74Q43714302-49311D57-C30D-4C8D-9852-AE97ABD8B3ACQ44124753-F9869913-D859-40F3-AE9E-C336FC9D584EQ47365250-2545FADA-749D-4BCF-B511-D0F55BEE8778Q48105200-8E39DC30-62FA-4CAA-BCFA-68CAE518E820Q48191012-B4418F30-361B-4613-98A0-FA4E66CA49AEQ50908946-F9D67E01-42E1-4DA1-BDC8-259628622929Q51868858-43F557AA-C0CB-4DD3-A3B2-B904FD970D39Q57129133-92A6B3AB-683B-4AAE-9116-8BCAD07DF7DCQ57386663-0C3206FF-0624-4FC0-B23D-F3CBE3FD00C5
P2860
Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Teratogen update: thalidomide: ...... ndings and new potential uses.
@ast
Teratogen update: thalidomide: ...... ndings and new potential uses.
@en
type
label
Teratogen update: thalidomide: ...... ndings and new potential uses.
@ast
Teratogen update: thalidomide: ...... ndings and new potential uses.
@en
prefLabel
Teratogen update: thalidomide: ...... ndings and new potential uses.
@ast
Teratogen update: thalidomide: ...... ndings and new potential uses.
@en
P2860
P1476
Teratogen update: thalidomide: ...... ndings and new potential uses.
@en
P2093
Strömland K
P2860
P304
P356
10.1002/(SICI)1096-9926(199911)60:5<306::AID-TERA11>3.0.CO;2-Y
P577
1999-11-01T00:00:00Z